The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Only one new molecular entity (NME) has been approved thus far in June. NMEs are a key measure of drug innovation as they contain active ingredients yet to be approved by the Food and Drug Administration (FDA). Alnylam Pharmaceutical Inc's (NASDAQ: ALNY) RNAi therapeutic Vutrisiran received approval for treating polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
